ArticlePloS one2025

Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line systemic therapies for hepatocellular carcinoma: A real-world study.

Sangdao Boonkaya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.